The Efficacy of Kohl (Surma) and Erythromycin in Treatment of Blepharitis: An Open-Label Clinical Trial

Esmat Karbassi,1 Ehsan Amiri-Ardekani2,3,4,5,6 Alireza Farsinezhad,5,6 Armita Shahesmaeili,7 Yasaman Abhari,8 Mahsa Ziaesistani,5,6 Noushin Pouryazdanpanah,5,6 Ali Derakhshani,5,6 Fatemeh Jamshidi,3,9 and Haleh Tajadini10,11

1Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
2Department of Phytopharmaceuticals (Traditional Pharmacy), Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
3Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
4Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
5Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical Sciences, Kerman, Iran
6Department of Hematology and Laboratory Sciences, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
7HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
8Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
9Student Association of Indigenous Knowledge, Shiraz University of Medical Sciences, Shiraz, Iran
10Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran
11Department of Traditional Medicine, School of Persian Medicine, Kerman University of Medical Sciences, Kerman, Iran

Correspondence should be addressed to Ehsan Amiri-Ardekani; ehsanamiri@sums.ac.ir and Haleh Tajadini; dr_haleh@yahoo.com

Received 27 September 2021; Revised 26 December 2021; Accepted 28 December 2021; Published 24 January 2022

Academic Editor: Francisca Rius Diaz

Copyright © 2022 Esmat Karbassi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Blepharitis is a common and chronic form of eyelid inflammation. Blepharitis treatment aims to decrease symptoms through antibacterial effects. One of the most common treatments of eyelid diseases in traditional medicine is using kohl. This clinical trial aimed to investigate its efficacy as a complementary treatment in staphylococcal blepharitis through an open-label clinical trial. Materials and Methods. Thirty patients were randomized to receive kohl in one eye contralateral and erythromycin ointment in another eye for 90 days. At baseline and after 90 days of treatment, symptoms, clinical signs, and side effects of treatments were recorded. Statistical analysis was carried out using SPSS software, version 19. Results. Despite randomization, there was a significant difference between the intervention and control eyes in the baseline mean clinical score (intervention eye: 9.86 (2.95) and control eye: 4.30 (2.81), \( P < 0.001 \)). The degree of reduction of related signs and symptoms in the eyes treated with kohl was significantly higher than that in the control group: (5.2 vs. 2.20, \( P < 0.001 \)) for symptoms and (7.40 vs. 2.46, \( P < 0.001 \)) for clinical signs. Cohen’s \( d \) statistic for mean difference of sign and symptom was 2.4 and 1.75, respectively, indicating a very strong effect. Conclusion. The present study results demonstrated a significant improvement in blepharitis-related signs and symptoms. The degree of improvement in the eyes treated with kohl was much higher than that in the control eyes.
1. Introduction

Blepharitis is one of the most common eye diseases that an ophthalmologist faces in the clinic. The etiology of blepharitis is not completely determined yet, but bacteria overload and the inflammation due to a load of bacteria have a significant role in developing the disease. Blepharitis is divided into two anterior and posterior blepharitis classifications. In anterior blepharitis, anterior lid margins are involved, while posterior blepharitis happens due to meibomian glands dysfunctions [1–3].

Staphylococcal blepharitis refers to accumulation of *Staphylococcus* epidermis in the eyelid. *Staphylococcus* produces enzymes and toxins (lipase, cholesterol esterase, and different lipid acids) that are harmful for eye tissues and causes eyelid inflammation and keratitis. Built toxins cause injury to the epithelium of the adjacent areas of eyelashes and consequently lead to fibrin formation and debride segments around eyelashes. The microbe might involve deeper cells of sebaceous glands and cause pigmentation, misdirection, and loss of eyelashes [4, 5]. The most important symptoms in all types of blepharitis are burning and irritation that is more severe in the morning and relieved during the day. Other symptoms include eye itching and discomfort after working with a computer, heaviness sensation in eyelids, secretions on eyelids, dry sensation, crusty eyelids on awakening, and red eyes. Furthermore, patients might complain of contact lenses intolerance. Clinical findings, based on the type of blepharitis, include collarette around eyelashes, lids’ margin thickening and hyperemia, eyelash loss and misdirection and plugging of meibomian gland orifices that can be resulted in complications such as marginal ulceration of cornea, conjunctival or corneal phlyctenulosis. The most crucial symptom of staphylococcal blepharitis is eye burning and irritation in the morning due to the accumulation of microbial toxins on the cornea during sleep. This symptom is gradually improved during the day with blinking and tears flow [5–7].

Treatment goals in blepharitis are decreasing symptoms, the number of bacteria in eyelid margins and inflammation as well as improving the function of meibomian gland that are achieved through washing and warm compress of eyelids, and the use of anti-inflammatory and antibacterial agents such as erythromycin, tobramycin, cyclosporine, local dexamethasone, and oral doxycycline [8–11].

Persian medicine scientists like Razus and Avicenna have mentioned therapeutic strategies for several diseases, including eye diseases, by compiling their own scientific findings and medical findings of other nations. Identification, diagnosis, and treatment of diseases have been developed for centuries. Fortunately, a comprehensive explanation of signs and symptoms of diseases has been provided in ancient Persian medicine texts. It should be mentioned that Persian medicine, due to its philosophical and logical bases, has special attention to the causes and symptoms of diseases and the process through which symptoms are improved by removing the causes of infection [12, 13].

In Persian medicine, blepharitis has been explained in eyelid diseases section. One of the most common treatments of eyelid diseases in Persian medicine texts is using kohl. Kohl, called surma in Persian, is a mineral substance with cold and dry nature. According to Persian medicine, it has several benefits. Traditional healers have paid special attention to the treatment of eye diseases, for example, applying kohl on the eyelid can prevent cataracts and eye ulcers. According to Persian medicine, kohl is an eye tonic and preserves eye health. Avicenna in Ghanoon claims that kohl destroys any type of infection and secretions resulting from intraocular lesions and maintains eye health [12, 14, 15]. Considering the mentioned points about kohl efficacy in treating ocular infections based on Ancient Persian medicine texts, we aimed to compare kohl efficacy and safety in a clinical trial with ocular erythromycin in blepharitis treatment.

2. Methods and Study Design

2.1. Subjects. This clinical trial was a prospective, three-month, self-controlled, paired eye trial that aimed to evaluate the efficiency of consuming kohl in treating blepharitis. This clinical trial complies with the CONSORT guideline.

Participants were chosen from patients who had been referred to the ophthalmology clinic in Kerman, Iran, and diagnosed with blepharitis. There was no age or gender limitation. All patients with staphylococcal blepharitis and/or meibomian gland dysfunction were included. Patients with anterior surface problem, glaucoma, and those who did not cooperate were excluded. Pregnant cases and patients with underlying diseases were excluded. As we did not find any previous investigation on kohl efficiency on blepharitis, this study was conducted on 30 patients automatically/pilot; therefore, sample size was not measured. In this study, Random Allocation software was used to generate the eyes, left and right, to therapeutic groups, in the matter of fact the compared groups are the two eyes of the patients. Random allocation sequence was conducted by the consultant of project using the mentioned software and was given to the clinic secretary. After referring of each patient, the secretary, who had no contribution in the treatment process, would check the list and inform the physician about what treatment should be given to which eye (Figure 1).

2.2. Intervention. Subjects were assigned to receive kohl and erythromycin ointment in contralateral of each eye for consecutive 90 days after obtaining informed consent. All participants were treated with Fluticort® (fluorometholone) eye drop twice a day and irrigation of eyelids with EyeSol® shampoo every night. Kohl was provided from the local market of Mecca, Saudi Arabia, and microbial and liver toxicity tests were performed before using in this study. After confirming its safety, it was powdered and put in kohl-dan (a small pot for holding surma) to be used by cases.
2.3. Clinical Measurement. Clinical measurements were conducted following the TFOS DEWS II Diagnostic Methodology Subcommittee [16] at baseline, day 90 of the treatment period. Symptoms, clinical signs, and side effects of treatment were recorded in each session. The symptoms that have been assessed through self-reporting of patients were itching, burning, redness, and sensation. The clinical signs, including redness, plug, swelling, chalazion, crust, madarosis, and inflammation, were evaluated by an ophthalmologist. All of these items scored on a 0–4 scale (Table 1). The total score for related symptoms and signs were calculated by summing up scores assigned to each item.

The treatment side effects, including increased inflammation and keratitis, were also assessed. Participants were asked to contact the clinic in case of any side effects.

2.4. Ethics. All patients were asked to sign the written informed consent before participation in study. For patients under 18 years, consent was obtained from their parents. The Ethics Committee of Kerman University of Medical Sciences approved this study protocol (IRCT201208017219N4, https://www.irct.ir), and the study was performed following the last version of Helsinki ethical guidelines.

2.5. Statistical Analysis. Statistical analysis was done using SPSS Ver.19. Mean and standard deviation of global sign and symptom scores were calculated and compared at baseline and follow-up sessions in each treatment group and between two treatments using the paired t-test. To measure the clinical significance of intervention, Cohen’s d statistic was calculated. P values less than 0.05 were considered significant.

3. Result

Patients’ age was from 6 to 70 years with a mean ± SD of 26.33 ± 1.64 years. Most of the participants were female (23 female and 7 male). At baseline, all eyes in the treatment of kohl and erythromycin indicated clinical signs of anterior blepharitis and meibomian gland dysfunction. The response
rate at the follow-up session was 100%. Despite the random allocation of treatments, the mean score of symptoms at baseline for the intervention eye was 6.56 ± 2.45, significantly higher than that for the control eye 3.23 ± 1.73 (P < 0.001). There was also a significant difference between the intervention and control eyes in the baseline mean clinical score intervention eye 9.86 ± 2.95 and control eye 4.30 ± 2.81 (P < 0.001). After 90 days of treatment, the patient’s signs and symptoms in both treatment groups significantly improved compared to baseline. Both symptom and sign scores at follow-up sessions among the eyes treated with erythromycin were lower than those in the eyes treated with kohl. Since the baseline signs and symptoms of the treated eyes were significantly more severe than the control eyes, comparing corresponding scores between the two treatment groups at follow-up sessions might be misleading. Therefore, we compared the degree of improvement in each group (calculated as differences between pre and post-treatment scores) as the outcome measure. The degree of reduction of related signs and symptoms in the eyes treated with kohl was significantly higher than the control group (5.2 vs. 2.2) (P < 0.001) for symptoms and (7.4 vs. 2.46) (P < 0.001) for clinical signs (Table 2). Also, Cohen’s d statistic for mean difference of sign and symptom was 2.4 and 1.75, respectively, which indicates a very strong effect.

4. Discussion

4.1. Clinical Finding. The present study’s findings demonstrated a significant improvement in blepharitis signs and symptoms in both treatment and control eyes. Significant reductions in symptomology scores were reported in treated eyes after 90 days. The degree of improvement in the eyes treated with kohl was much higher than that in the control eyes. Many patients affected by blepharitis with symptoms of ocular surface are important to looking for more effective management and to prevent adverse outcomes. There are many conventional treatment suggested by researchers because of not definite response to them. They suggested further studies to understanding of the etiology and associated factors and management of blepharitis.

There is no definitive cure for blepharitis, and the main goal of treatment is to reduce the symptoms as much as feasible. The duration of treatment varies depending on the severity of the disease and can differ from a few weeks to several months. Nonantibiotic treatments such as tear supplement, lid hygiene, and warm compresses are at the first line of treatment and are widely prescribed, which indicate that antibiotics are not the main treating option for blepharitis [17]. Topical antibiotics such as erythromycin only affect anterior blepharitis and are not sufficient in posterior blepharitis. Furthermore, the consuming of oral antibiotics did not significantly reduce the symptoms of blepharitis [18].

According to Lindesley, review of 34 studies on chronic blepharitis has revealed that warm compress of the eyes improves patients’ symptoms while they are not cured [18]. Studies on efficacy of tear supplements and eye hygiene reported reduced associated symptoms and improved eye comfort in patients [19, 20].

4.2. Therapeutic Effect. Badeeb et al. concluded that a culture medium containing kohl has an inhibitory effect on Staphylococcus growth [21]. According to Al-Kaff et al., kohl has an inhibitory effect against Staphylococcus [22]. Mahmood et al. reported that kohl led to increases in nitric oxide production with antimicrobial properties [23]. According to Gupta, kohl formulated has antimicrobial activity [24]. Kohl chemical composition can explain its antibacterial and anti-inflammatory properties. Chemical analysis of kohl indicates that the main elements of kohl include lead, sulphur, antimony, carbon, iron, and zinc [25]. Based on studies, sulphur nanoparticles have bactericidal efficacy against many bacteria, including Staphylococcus aureus [26]; furthermore, antimony has antibacterial activities [27]. There are zinc-dependent signaling pathways that affect reducing inflammation. Also, zinc has antioxidant activities [28, 29]. As reported, most kohl ingredients have antibacterial and anti-inflammatory effects, which explicate kohl’s efficacy in improving signs and symptoms of blepharitis.

4.3. Safety. Many studies have been done on lead poisoning in kohl with controversial results. Most lead poisoning cases have been seen in children as a small amount of lead is found in their blood samples. Studies suggest that the poisoning has not happened in eye contact [30, 31].

| Table 1: Scoring signs and symptoms of blepharitis patients. |
|---------------------------------------------------------------|
| **Symptoms** | 0 | 1 | 2 | 3 | 4 |
|--------------|---|---|---|---|---|
| Redness sign | Absent | Sometimes | Half of the times | Most of the times | Always |
| Plugin sign  | Clear orifices in the middle plugging <1/3 of orifices part of the lower lid | — | Plugin <1/3 to 2/3 of orifices | Plugin >2/3 of orifices | Plugin of all orifices |
| Swelling sign | Absent | Mild | Moderate | Sever | — |
| Crust sign   | Clear | Cloudy | Granular | Paste like | Nonexpressible |
| Madarosis sign | Absent | Mild | Moderate | Sever | — |
| Inflammation | Absent | Mild | Moderate | Sever | — |

*Including itching, burning, redness, and sensation in the eye.*
Nevertheless, other studies claimed kohl is safe to use as an eyeliner and does not have toxicity [32, 33].

Due to the observed positive effects of kohl on staphylococcal blepharitis in the present study and also its beneficial effects on eyesight mentioned in Persian medicine texts, further studies regarding to kohl are suggested.

4.4. Limitations. Studies on the effectiveness of kohl on blepharitis have been limited, and there was no possibility of proper comparison between the results. Also, no special method was used to determine the sample size, and patients who met the inclusion criteria were included in this trial, which is one of the limitations of the study. In addition, in this study, the group treated with kohl and the group treated with erythromycin were the same, and comparison was done between the eyes of the same group of people, while if the case and control groups were selected separately, the efficacy of kohl would be better evaluated.

5. Conclusion

The results of this study indicate that kohl compounds and their anti-inflammatory effects can effectively reduce the symptoms of blepharitis patients. Kohl was more effective in reducing the symptoms of blepharitis than erythromycin, which makes it a good option for treating this disease. Further studies are needed to evaluate the efficacy, potential toxicity, and optimal dose and duration of kohl in blepharitis treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This article was written with the support of Kerman University of Medical Sciences.

References

[1] A. Rodriguez-Garcia, D. Loya-Garcia, E. Hernandez-Quintela, and A. Navas, “Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study,” Clinical Ophthalmology (Auckland, NZ), vol. 13, p. 53, 2019.

[2] A. B. Huggins, J. R. Carrasco, and R. C. Eagle Jr, “MEN 2B masquerading as chronic blepharitis and euryblepharon,” Orbit, vol. 38, no. 6, pp. 514–518, 2019.

[3] F. D. Choi, M. L. Juhasz, and N. A. Mesinkovska, “Topical ketocnazole: a systematic review of current dermatological applications and future developments,” Journal of Dermatological Treatment, vol. 30, 2019.

[4] K. Duncan and B. H. Jeng, “Medical management of blepharitis,” Current Opinion in Ophthalmology, vol. 26, no. 4, pp. 289–294, 2015.

[5] C. Putnam, “Diagnosis and management of blepharitis: an optometrist’s perspective,” Clinical Optometry, vol. 8, pp. 71–78, 2016.

[6] M. Eberhardt and G. Rammohan, Blepharitis, StatPearls Publishing, Treasure Island, FL, USA, 2017.

[7] M. A. Lemp and K. K. Nichols, “Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment,” The Ocular Surface, vol. 7, no. 2, pp. S1–S14, 2009.

[8] K. Hosseini, L. B. Bourque, and R. D. Hays, “Development and evaluation of a measure of patient-reported symptoms of blepharitis,” Health and Quality of Life Outcomes, vol. 16, no. 1, p. 11, 2018.

[9] P. Khoo, K. G.-J. Ooi, and S. Watson, “Effectiveness of pharmaceutical interventions for meibomian gland dysfunction: an evidence-based review of clinical trials,” Clinical & Experimental Ophthalmology, vol. 47, no. 5, pp. 658–668, 2019.

[10] F. E. Hakim and A. V. Farooq, “Medical management of blepharitis,” in Blepharitis: A Comprehensive Clinical Guide, pp. 83–89, Springer, Berlin, Germany, 2021.

[11] R. F. Kissling, C. M. Sanfilippo, and H. H. DeCory, “Comparative in vitro activity of antibiotics frequently used in the management of staphylococcal blepharitis,” Investigative Ophthalmology & Visual Science, vol. 62, no. 8, p. 730, 2021.

[12] H. Namavar, M. M. Zeinabad, and H. Tajadini, “Standardization of traditional iranian medicine terminology,” QUID: Investigación, Ciencia y Tecnología, no. 1, pp. 2260–2266, 2017, https://dialnet.unirioja.es/servlet/articulo?codigo=6227124.
[13] R. Seifaddini, H. Tajadini, and R. Choopani, “Physiopathology of dementia from the perspective of traditional persian medicine,” Journal of Evidence-Based Complementary & Alternative Medicine, vol. 20, no. 3, pp. 224–227, 2015.

[14] E. A. Ardekani, H. Askari, and A. Mohagheghzadeh, “Memorial functional foods: a new concept from bavi tribe,” Journal of Ethnic Foods, vol. 7, no. 1, pp. 1–10, 2020.

[15] A. M. Jaladat, E. Amiri-Ardekani, P. S. Ramezani, M. Boroughani, M. E. Alorizi, and M. M. Parvizi, “Correlation between gastrointestinal symptoms and adherence to traditional persian medicine dietary recommendations in patients with vitiligo; a cross-sectional study,” Journal of Complementary and Integrative Medicine, vol. 18, 2021.

[16] J. S. Wolffsohn, R. Arita, R. Chalmers et al., “TFOS DEWS II diagnostic methodology report,” The Ocular Surface, vol. 15, no. 3, pp. 539–574, 2017.

[17] M. S. Milner, K. A. Beckman, J. I. Luchs et al., “Dysfunctional tear syndrome: dry eye disease and associated tear film disorders—new strategies for diagnosis and treatment,” Current Opinion in Ophthalmology, vol. 28, no. 1, p. 3, 2017.

[18] K. Lindsley, S. Matsumura, E. Hatef, and E. K. Akpek, “Interventions for chronic blepharitis,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD005556, 2012.

[19] O. Murphy, V. O’Dwyer, and A. Lloyd-McKernan, “The effect of lid hygiene on the tear film and ocular surface, and the prevalence of demodex blepharitis in university students,” Contact Lens and Anterior Eye, vol. 43, no. 2, pp. 159–168, 2020.

[20] M. Guillon, C. Maissa, and S. Wong, "Symptomatic relief associated with eyelid hygiene in anterior blepharitis and MGD," Eye & Contact Lens: Science & Clinical Practice, vol. 38, no. 5, pp. 306–312, 2012.

[21] O. Badeeb, R. Ajlan, M. Walid, and K. Al-Ethmed, “Kohl al-ethmed,” Journal of King Abdulaziz University-Medical Sciences, vol. 15, no. 4, pp. 59–67, 2008.

[22] A. Al-Kaff, A. Al-Rajhi, K. Tabbara, and A. El-Yazigi, "Kohl-the traditional eyeliner: use and analysis," Annals of Saudi medicine, vol. 13, no. 1, pp. 26–30, 1993.

[23] Z. A. Mahmood, I. Azhar, and S. W. Ahmed, “Kohl use in antiquity: effects on the eye,” Toxicology in Antiquity, Elsevier, Amsterdam, Netherlands, pp. 93–103, 2019.

[24] R. Gupta, “Formulation, preliminary evaluation and antimicrobial activity of a herb based kohl,” International Journal of Phytochemistry and Natural Ingredients, vol. 3, no. 1, p. 5, 2016.

[25] P. H. Ullah, Z. A. Mahmood, M. Sualeh, and S. M. Zoha, “Studies on the chemical composition of kohl stone by X-ray diffractometer,” Pakistan Journal of Pharmaceutical Sciences, vol. 23, pp. 48–52, 2010.

[26] P. Paralikar and M. Rai, “Bio-inspired synthesis of sulphur nanoparticles using leaf extract of four medicinal plants with special reference to their antibacterial activity,” IET Nanobiotechnology, vol. 12, no. 1, pp. 25–31, 2018.

[27] H. P. S. Chauhan, A. Bakshi, and S. Bhatiya, “Synthesis, spectroscopic characterization and antibacterial activity of antimony(III) bis(dialkyldithiocarbamate)alkylidithiocarbonates,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 81, no. 1, pp. 417–423, 2011.

[28] M. Jarosz, M. Olbert, G. Wyszogrodzka, K. Młyniec, and T. Librowski, “Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-kB signaling,” Inflammopharmacology, vol. 25, no. 1, pp. 11–24, 2017.

[29] A. S. Prasad, “Zinc is an antioxidant and anti-inflammatory agent: its role in human health,” Frontiers in Nutrition, vol. 1, no. 8, p. 14, 2014.

[30] S. A. F. Al-Hazzaa and P. M. Krahn, “Kohl: a hazardous eyeliner,” International Ophthalmology, vol. 19, no. 2, pp. 83–88, 1995.

[31] E. Tiffany-Castiglioni, R. Barhoumi, and Y. Mounime, "Kohl and surma eye cosmetics as significant sources of lead (Pb) exposure," Journal of Local and Global Health Science, vol. 2012, no. 1, p. 1, 2012.

[32] A. Mohta, “Kajal (kohl)-a dangerous cosmetic,” Oman Journal of Ophthalmology, vol. 3, no. 2, p. 100, 2010.

[33] Z. A. Mahmood, S. M. Zoha, K. Usmanghani et al., “Kohl (surma): retrospect and prospect,” Pakistan Journal of Pharmaceutical Sciences, vol. 22, no. 1, pp. 107–122, 2009.